Advertisement

Topics

Bluebird prices gene therapy at 1.58 million euros over 5 years

10:56 EDT 14 Jun 2019 | Reuters

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Original Article: Bluebird prices gene therapy at 1.58 million euros over 5 years

NEXT ARTICLE

More From BioPortfolio on "Bluebird prices gene therapy at 1.58 million euros over 5 years"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...